Cargando…
Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is an unsolved and growing concern in cardiovascular medicine. While no treatment options that improve prognosis in HFpEF patients has been established so far, SGLT2 inhibitors (SGLT2i) are currently being investigated for the treatment of HFpEF...
Autores principales: | Pabel, Steffen, Hamdani, Nazha, Singh, Jagdeep, Sossalla, Samuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602188/ https://www.ncbi.nlm.nih.gov/pubmed/34803735 http://dx.doi.org/10.3389/fphys.2021.752370 |
Ejemplares similares
-
SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
por: Pabel, Steffen, et al.
Publicado: (2021) -
Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction
por: Budde, Heidi, et al.
Publicado: (2022) -
Treatment of Heart Failure With Normal Ejection Fraction
por: Hamdani, Nazha, et al.
Publicado: (2010) -
Novel Mechanisms in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Lakhani, Ishan, et al.
Publicado: (2019) -
Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
por: Clemmer, John S., et al.
Publicado: (2023)